Compare HSBC Holdings plc (HSBC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs TransMedics Group Inc — how do they compare? HSBC Holdings plc trades at $103.25 (market cap $347.63B), while TransMedics Group Inc trades at $70.87 (market cap $2.57B). The key difference: HSBC Holdings plc is far larger — about 135.3× TransMedics Group Inc's market cap, and HSBC Holdings plc pays a 3.71% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| HSBC | TMDX | |
|---|---|---|
Market Cap | $347.63B | $2.57B |
Sector | Technology | Technology |
52-Week High | $101.12 | $150.42 |
52-Week Low | $61.30 | $61.99 |
Dividend Yield | 3.71% | — |
Enterprise Value | — | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $99.01, down 1.59% today but near its 52-week high of $99.47. The stock shows bullish technical momentum with strong moving average support and recent earnings beats in Q3 and Q4 2025. Revenue grew to $71.02B in 2025 with a healthy 30.81% net margin, though Q1 2026 missed expectations. Analyst sentiment is mixed with 38% buy ratings while the company executes strategic moves including AI partnerships and business portfolio optimization.
HSBC presents a balanced opportunity with solid profitability and strategic repositioning, but faces execution risks in its global restructuring. The current valuation at 16.37 P/E appears reasonable for a global bank, though regulatory challenges and market volatility require monitoring. Near-term catalysts include the upcoming Q2 earnings and continued progress on business simplification initiatives.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
